Weekly Investment Analysts' Ratings Changes for BioCryst Pharmaceuticals


8/10/2017 - BioCryst Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. According to Zacks, "BioCryst Pharmaceuticals, Inc. is a leader in the use of crystallography and structure-based drug design for the development of novel therapeutics to treat cancer, cardiovascular diseases, autoimmune diseases, and viral infections.



from Biotech News